Clozapine Toxicity Unveiled: Cerebral Edema as a Rare and Alarming Complication
Location
Center for Advanced Learning and Simulation (CALS)
Publication Date
April 2025
Start Date
17-4-2025 8:00 AM
Description
Introduction: Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia which requires careful monitoring due to its extensive side effect profile. While its neurotoxic effects are well-documented, cerebral edema remains a rare and underrecognized complication of clozapine toxicity. We present a case of cerebral edema associated with severe clozapine toxicity, highlighting the need for awareness of this potentially life-threatening manifestation. Case Presentation: A 40-year-old female with schizophrenia, hypothyroidism, and hyperlipidemia presented with altered mental status for 2–3 days, accompanied by decreased oral intake, poor hygiene, and incoherent speech. At baseline, she was independent in daily activities and conversant. She resided in a group home and was prescribed clozapine 100 mg twice daily. On admission, she was diagnosed with Escherichia coli bacteremia and AKI, warranting antibiotics and dialysis. Despite treatment, her mental status did not improve. Further neurological evaluation included a serum clozapine level which was critically elevated at 1788 ng/mL and a brain MRI revealing cerebral edema with posterior fossa fullness and low-lying cerebellar tonsils. A dexamethasone regimen was initiated, resulting in significant neurological recovery. Discussion: While clozapine toxicity typically presents with sedation, hypotension, tachycardia, and seizures, cerebral edema is an exceedingly rare manifestation. The elevated clozapine level, likely exacerbated by renal dysfunction, contributed to toxicity and neurological decline. The resolution of symptoms with dexamethasone suggests that cerebral edema in this context may be reversible with timely intervention. Conclusion: This case emphasizes the importance of recognizing cerebral edema as a rare yet serious complication of clozapine toxicity. Clinicians should monitor clozapine levels closely, particularly in patients with renal impairment, to mitigate the risk of severe neurological outcomes.
Recommended Citation
Meyer, Lauren BS; Mikhael, Eremy MD; and El-Abassi, Rima MD, "Clozapine Toxicity Unveiled: Cerebral Edema as a Rare and Alarming Complication" (2025). Dept. of Psychiatry Research Symposium. 23.
https://digitalscholar.lsuhsc.edu/psych_rd/2025/presentations/23
Clozapine Toxicity Unveiled: Cerebral Edema as a Rare and Alarming Complication
Center for Advanced Learning and Simulation (CALS)
Introduction: Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia which requires careful monitoring due to its extensive side effect profile. While its neurotoxic effects are well-documented, cerebral edema remains a rare and underrecognized complication of clozapine toxicity. We present a case of cerebral edema associated with severe clozapine toxicity, highlighting the need for awareness of this potentially life-threatening manifestation. Case Presentation: A 40-year-old female with schizophrenia, hypothyroidism, and hyperlipidemia presented with altered mental status for 2–3 days, accompanied by decreased oral intake, poor hygiene, and incoherent speech. At baseline, she was independent in daily activities and conversant. She resided in a group home and was prescribed clozapine 100 mg twice daily. On admission, she was diagnosed with Escherichia coli bacteremia and AKI, warranting antibiotics and dialysis. Despite treatment, her mental status did not improve. Further neurological evaluation included a serum clozapine level which was critically elevated at 1788 ng/mL and a brain MRI revealing cerebral edema with posterior fossa fullness and low-lying cerebellar tonsils. A dexamethasone regimen was initiated, resulting in significant neurological recovery. Discussion: While clozapine toxicity typically presents with sedation, hypotension, tachycardia, and seizures, cerebral edema is an exceedingly rare manifestation. The elevated clozapine level, likely exacerbated by renal dysfunction, contributed to toxicity and neurological decline. The resolution of symptoms with dexamethasone suggests that cerebral edema in this context may be reversible with timely intervention. Conclusion: This case emphasizes the importance of recognizing cerebral edema as a rare yet serious complication of clozapine toxicity. Clinicians should monitor clozapine levels closely, particularly in patients with renal impairment, to mitigate the risk of severe neurological outcomes.